WHO said on Aug. 20, 2026 that Congo will receive 70,000 Ervebo doses.
Why it matters: The shipment shows how regulators and health agencies can use a licensed vaccine under emergency guidance when an outbreak is caused by a different Ebola strain. It also highlights the tradeoffs in allocating limited supply between clinical trials and frontline protection during a fast-moving response.
- WHO and partners announced 70,000 Ervebo Ebola vaccine doses for the Democratic Republic of the Congo.
- WHO said 20,000 doses will go into a Phase 3 clinical trial and 50,000 into frontline and health workers.
- The outbreak is caused by Bundibugyo virus, while Ervebo is approved for Zaire ebolavirus.
- WHO's Aug. 12 update said the outbreak had reached 4,665 confirmed cases and 2,184 deaths across 54 health zones in six provinces.
The Democratic Republic of the Congo will receive 70,000 doses of the Ervebo Ebola vaccine as officials respond to an outbreak caused by Bundibugyo virus, according to the World Health Organization and partners.
WHO said the shipment was announced on Aug. 20, 2026. Of the doses, 20,000 will be used in a Phase 3 clinical trial, while 50,000 will go to frontline and health workers. The decision reflects WHO emergency guidance for using a licensed Ebola vaccine during Bundibugyo outbreaks, even though Ervebo is approved for Zaire ebolavirus, not Bundibugyo virus. WHO guidance on vaccine use in Bundibugyo outbreaks sets out that regulatory framework.
The scale of the outbreak remains severe. WHO said in its Aug. 12 update that the disease had spread across 54 health zones in six provinces, with 4,665 confirmed cases and 2,184 deaths. WHO's outbreak update details the latest case counts and spread. The agency declared the epidemic a public health emergency of international concern on May 17, 2026. WHO's emergency declaration explains the basis for the international response.
Ervebo was approved by the FDA in December 2019 for prevention of Ebola disease caused by Zaire ebolavirus. FDA approval letter for Ervebo provides the labeled indication. AP's account of the Congo vaccine shipment reported that officials are relying on the vaccine's past use in Ebola responses even as the current outbreak involves a different strain.
By the numbers
- 70,000 - total Ervebo doses announced for Congo
- 4,665 - confirmed cases in WHO's Aug. 12 outbreak update
- 2,184 - deaths reported across six provinces
Yes, but: Ervebo is being used under emergency guidance for a different Ebola strain than the one it is licensed to prevent.
What's next: WHO said 20,000 doses will be used in a Phase 3 clinical trial and 50,000 will go to frontline and health workers.